FI20116181A - Uusia terapeuttisia vektoreita - Google Patents

Uusia terapeuttisia vektoreita Download PDF

Info

Publication number
FI20116181A
FI20116181A FI20116181A FI20116181A FI20116181A FI 20116181 A FI20116181 A FI 20116181A FI 20116181 A FI20116181 A FI 20116181A FI 20116181 A FI20116181 A FI 20116181A FI 20116181 A FI20116181 A FI 20116181A
Authority
FI
Finland
Prior art keywords
new therapeutic
therapeutic vectors
vectors
new
therapeutic
Prior art date
Application number
FI20116181A
Other languages
English (en)
Swedish (sv)
Other versions
FI123955B (fi
Inventor
Tuuli Ranki
Akseli Hemminki
Vincenzo Cerullo
Anniina Koski
Original Assignee
Oncos Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncos Therapeutics Ltd filed Critical Oncos Therapeutics Ltd
Priority to FI20116181A priority Critical patent/FI123955B/fi
Priority to PCT/FI2012/051162 priority patent/WO2013076374A1/en
Priority to EP15186798.3A priority patent/EP3006566A1/en
Priority to US14/359,141 priority patent/US9410129B2/en
Priority to EP12852023.6A priority patent/EP2783005A4/en
Publication of FI20116181A publication Critical patent/FI20116181A/fi
Application granted granted Critical
Publication of FI123955B publication Critical patent/FI123955B/fi
Priority to US14/866,582 priority patent/US20160082100A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8616—Special methods for targeting systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material
    • C12N2710/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI20116181A 2011-11-25 2011-11-25 Onkolyyttinen adenovirus FI123955B (fi)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20116181A FI123955B (fi) 2011-11-25 2011-11-25 Onkolyyttinen adenovirus
PCT/FI2012/051162 WO2013076374A1 (en) 2011-11-25 2012-11-23 Recombinant serotype 5 (ac!5) adenoviral vectors
EP15186798.3A EP3006566A1 (en) 2011-11-25 2012-11-23 Recombinant serotype 5 (ac]5) adenoviral vectors
US14/359,141 US9410129B2 (en) 2011-11-25 2012-11-23 Recombinant serotype 5 (Ad5) adenoviral vectors
EP12852023.6A EP2783005A4 (en) 2011-11-25 2012-11-23 NEW THERAPEUTIC VECTORS
US14/866,582 US20160082100A1 (en) 2011-11-25 2015-09-25 RECOMBINANT SEROTYPE 5 (Ad5) ADENOVIRAL VECTORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20116181 2011-11-25
FI20116181A FI123955B (fi) 2011-11-25 2011-11-25 Onkolyyttinen adenovirus

Publications (2)

Publication Number Publication Date
FI20116181A true FI20116181A (fi) 2013-05-26
FI123955B FI123955B (fi) 2014-01-15

Family

ID=48469205

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20116181A FI123955B (fi) 2011-11-25 2011-11-25 Onkolyyttinen adenovirus

Country Status (4)

Country Link
US (2) US9410129B2 (fi)
EP (2) EP2783005A4 (fi)
FI (1) FI123955B (fi)
WO (1) WO2013076374A1 (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787645B2 (en) 2013-04-18 2020-09-29 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013211871B2 (en) 2012-01-25 2017-12-14 Board Of Regents, The University Of Texas System Biomarkers and combination therapies using oncolytic virus and immunomodulation
CN104271748B9 (zh) 2012-02-02 2019-05-24 得克萨斯州大学系统董事会 表达异源肿瘤相关抗原的腺病毒
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
WO2014204814A1 (en) * 2013-06-18 2014-12-24 Dnatrix, Inc. Treatment of brain cancer with oncolytic adenovirus
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
CN104328140B (zh) * 2014-10-08 2018-06-05 兰州大学 一种高嗜性膀胱癌靶向性肿瘤杀伤腺病毒
US10617729B2 (en) * 2014-12-24 2020-04-14 The Uab Research Foundation Multitargeting onocolytic adenovirus, methods of use, and methods of making
US10888609B2 (en) 2015-11-03 2021-01-12 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN108699566B (zh) 2016-02-23 2023-06-30 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
US10076562B2 (en) 2016-04-19 2018-09-18 The Board Of Regents Of The University Of Texas System Methods for treating plague
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
CN110114461A (zh) 2016-08-17 2019-08-09 博德研究所 新型crispr酶和系统
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
JP7242534B2 (ja) * 2017-01-30 2023-03-20 エピセントアールエックス，インコーポレイテッド 腫瘍選択的なｔａｔａボックスおよびｃａａｔボックスの変異体
US20200405639A1 (en) 2017-04-14 2020-12-31 The Broad Institute, Inc. Novel delivery of large payloads
NZ758626A (en) 2017-04-21 2023-09-29 Baylor College Medicine Oncolytic virotherapy and immunotherapy
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
WO2019132594A1 (ko) * 2017-12-29 2019-07-04 한양대학교 산학협력단 유전자 전달용 세포 시트
WO2020131862A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
US20220220469A1 (en) 2019-05-20 2022-07-14 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
JP2023505925A (ja) * 2019-10-11 2023-02-14 ティルト バイオセラピューティクス オサケユキチュア バリアント型インターロイキン－２（ｖＩＬ－２）ポリペプチドをコードする腫瘍溶解性ウイルスベクター
EP4381082A1 (en) * 2021-08-06 2024-06-12 Theravax, Inc. Adenoviral vector-based vaccine for emerging viruses
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301575C (en) * 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
WO2009127666A2 (en) 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Method and compositions
EP2379586B1 (en) 2008-12-22 2016-11-02 Targovax Oy Oncolytic adenoviral vectors and methods and uses related thereto
US9345787B2 (en) 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787645B2 (en) 2013-04-18 2020-09-29 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy

Also Published As

Publication number Publication date
US20160082100A1 (en) 2016-03-24
US9410129B2 (en) 2016-08-09
EP3006566A1 (en) 2016-04-13
EP2783005A1 (en) 2014-10-01
US20150232811A1 (en) 2015-08-20
EP2783005A4 (en) 2015-07-22
WO2013076374A1 (en) 2013-05-30
FI123955B (fi) 2014-01-15

Similar Documents

Publication Publication Date Title
FI20116181A (fi) Uusia terapeuttisia vektoreita
CO7020866A2 (es) Péptidos terapéuticos
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
BR112014002399A2 (pt) conjunto
BR112014004902A2 (pt) peptídeos
DK2769050T3 (da) Propsensor
DK2760886T3 (da) Immunocytokin-kombinationsterapi
FI20115876A0 (fi) Yhdistelmähoito
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
DE102011100082A8 (de) Traygreifvorrichtung
DK2783256T3 (da) Terapeutiske briller
DK3141251T3 (da) Koloskopi - forberedelse
CO6880064A2 (es) Métodos terapéuticos
DE112011104936A5 (de) Stanzstauchniet
FI20115640A0 (fi) Yhdistelmähoito
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild
DK2526750T3 (da) Høbjærgningsmaskine
DE112012001294T8 (de) Umspritzungsverfahren
FI10522U1 (fi) Sihti
DE102011117169A8 (de) Absetzplattenanordnung

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 123955

Country of ref document: FI

Kind code of ref document: B